Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company committed to developing IRX-2, a novel cytokine-based therapy, to treat patients with cancer. IRX-2 delivers IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.
In a Phase 2A clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer.
Our headquarters, laboratories and manufacturing facilities are located in the historic Brooklyn Army Terminal.
The term “cytokine” is derived from a combination of two Greek words – “cyto” meaning cell and “kinos” meaning movement. Cytokines are cell signaling molecules that aid cell to cell communication in immune responses. They are any number of small proteins secreted by various cell types. These molecules carry signals locally and systemically to a variety of cells. They are responsible for up-regulating (turning on), as well as down-regulating (turning off) the immune response.
The immune system is also important in preventing and fighting cancer. Cancer can survive by blocking your immune system’s ability to detect and fight cancer.
Cancer patients often have a weakened immune system. One way that cancer weakens the immune system is by turning off the immune cells so that they are no longer able to fight the cancer. This may allow for the tumor to continue growing. If the tumor is removed, a weakened immune system may allow the cancer to come back.
Brooklyn ImmunoTherapeutics is developing IRX-2, which delivers IL-2 and other key cytokines, a unique formulation specifically designed to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.